본 컨퍼런스는 참가 신청이 마감되었습니다.

Leaders in BioBanking Congress 2015 - 바이오뱅크 리더 콩그레스 2015 -
2015년 7월 14 - 16일
캐나다 온타리오주 토론토, 인터컨티넨탈 토론토 센터

현재 생체 시료 수집은 다양한 연구 그룹이 시행하고 있으며, 목적도 기초 연구에서 임상시험에 이르기까지 다양합니다. 고품질 생물학적 연구를 위해서는 잘 관리된 바이오뱅크가 필수적입니다. 또한 생체 시료의 적절한 수집, 처리, 보존, 추적은 연구자가 분자 정보와 임상 정보를 더 나은 형태로 연결시킬 수 있다는 점에서 매우 중요한 요소입니다. 따라서 바이오뱅크가 과학과 비지니스에 모두 관련된 것은 당연하다고 할 수 있습니다.

Cambridge Healthtech Institute(CHI)가 주최하는 제7회 International Leaders in Biobanking Congress: Maximizing Your Investment in Biospecimens는 바이오뱅크의 비지니스와 과학 양측면에 초점을 맞춘 컨퍼런스입니다. 컨퍼런스에서는 생물 의학 및 생물 약제학 연구자, 규제기관 임원, Biorepository 관리자 및 직원 등이 한자리에 모여 현재 최첨단 생물 의학 연구에서 생체 시료를 효과적으로 이용하기 위한 최적의 전략을 탐구합니다.


프리컨퍼런스 | 첫째날 | 둘째날 | 셋째날 | 포스트컨퍼런스 | 연사


7월 13일(월)

1:00 pm 쇼트코스 등록


1:30-5:30 프리컨퍼런스 쇼트코스*

* 별도 참가 등록 필요


5:00 메인컨퍼런스 등록


연구시설 현장 투어 및 리셉션:University Health Network(UHN)의 생체 시료 연구 프로그램

(참가 정원 50명)

6:00-8:00

5:45 연구시설 현장 투어 셔틀버스 출발

* Intercontinental Toronto Centre와 연구시설을 왕복하는 셔틀 서비스 무료 제공

6:00-8:00 현장 투어 및 리셉션:UHN의 생체 시료 연구 프로그램

This tour at Canada's largest academic hospital system begins in surgical pathology with the banking of complex surgical specimens and data entry into our customized caTissueSuite research specimen management system. The tour continues to our laboratories for a demonstration of our state-of-the-art biospecimen information technology system, digital image analysis and laser capture microdissection.

8:00 셔틀 버스로 호텔로 이동

8:15 프리컨퍼런스 세션 종료


프리컨퍼런스 | 첫째날 | 둘째날 | 셋째날 | 포스트컨퍼런스 | 연사


7월 14일(화)

7:30 am 메인컨퍼런스 등록, 커피


기조 세션:요구되는 커뮤니티 전체

8:00 환영사 및 의장 개회사

Michael RoehrlMichael H. A. Roehrl, M.D., Ph.D., Director, UHN Program in BioSpecimen Sciences, University Health Network and University of Toronto

8:15 생체 시료 관리자로서 병리학자가 담당하는 책무의 복잡성

Sylvia AsaSylvia L. Asa, M.D., Ph.D., Pathologist-in-Chief, Medical Director, Laboratory Medicine Program, University Health Network; Lakeridge Health & Women's College Hospital; Senior Scientist, Ontario Cancer Institute; Professor, Laboratory Medicine & Pathobiology, University of Toronto

Pathologists have responsibility for handling patient biospecimens; they implement rigorous quality assurance of processes that determine how specimens are collected, processed, examined, reported and either destroyed, biobanked or retained on file. Pathology is ideally positioned to develop and oversee biobanks and because of its capacity for data generation, generally provides the greatest amount of information for specimen annotation. Pathology also is subject to mandatory requirements for retention of clinical records, including tissue blocks and slides, for legal and accreditation purposes, emphasizing the importance of collecting and documenting biospecimens for research.

9:00 전자건강기록(EHR) 연동 바이오뱅크를 이용한 발견과 실현:eMERGE 네트워크 경험

Rex ChisholmRex L. Chisholm, Ph.D., Vice Dean, Scientific Affairs and Graduate Education; Adam and Richard T. Lind Professor, Medical Genetics, Northwestern University Feinberg School of Medicine

Biobanks linked to electronic health records (EHR) provide a unique opportunity to study the association between genetic variation and phenotypes. The eMERGE network, funded by the National Human Genome Research Institute, has not only demonstrated the utility of this approach, but has also begun to develop methods for associating specific genomic variants with EHRs and providing clinical decision support to assist care providers in the use of this information.

9:45 휴식시간

10:15 향후 이용을 위한 연구 시료 조제:기능성 품질관리 평가를 위한 혁신적 방법과 바이오뱅크 베스트 프랙티스

Andrew BrooksAndrew Brooks, Ph.D., COO, RUCDR Infinite Biologics; Associate Professor, Genetics, Rutgers University

The presentation focuses on biomarker development and translational research optimization by taking into account how samples are collected, selection of the best technology for sample bioprocessing, global biobanking best practices and how information on each sample should be stored to enhance data sharing throughout the research process. Specific topics to be discussed include:

  • Sample bioprocessing and quality control methods that maximize the utility of collected biospecimens for current and future research
  • Understanding the power of evolving genomic technologies and how to develop a sample-centric roadmap for future research use
  • The role of centralized biobanking and global data integration in real-time data mining and optimization of biospecimen resources
  • How to build scientific and operational biomarker development synergies through collaborations to increase research productivity

11:00 Biorepository 네트워크를 위한 종합적 표준 작업 절차 작성 - CTRNet의 경험

Brent SchacterBrent Schacter, M.D., FRCPC, Principal Investigator, CTRNet; Professor, Department of Internal Medicine, Section of Hematology/Oncology, College of Medicine, University of Manitoba/CancerCare Manitoba

The Canadian Tissue Repository Network is a consortium of Canadian tumour biorepositories that aims to enhance biobanking capacity and quality through standardization. To minimize the issue of variable biobanking practices, CTRNet has developed and maintained a comprehensive set of standard operating procedures (SOPs). The key elements of the CTRNet SOP development process will be described. Once developed, reviewed and ratified by CTRNet, the SOPs have been published on our website for public access (with over 15,000 downloads in over 60 countries).

11:45 세션 종료

12:00 pm 오찬 프레젠테이션(스폰서 모집중) 또는 개별 점심식사


양질의 바이오뱅크 유지

2:00 의장 발언

Andrew BrooksAndrew Brooks, Ph.D., COO, RUCDR Infinite Biologics; Associate Professor, Genetics, Rutgers University

2:05 커뮤니티 병원 시스템의 전국적 생체 시료 수집 네트워크 구축과 실현

Jeffrey OttoJeffrey Otto, MBA, Ph.D., National Director, Center for Translational Research, Institute for Research and Innovation, Catholic Health Initiatives

Catholic Health Initiatives is the fifth-largest health system in the U.S., with 100+ hospitals spread nationally. Within this community hospital system, the Center for Translational Research (CTR) has built a first-of-its-kind hub-and-spoke biorepository program. Key attributes of this biorepository include: 1) high physical biospecimen quality, 2) EMR-linked patient data, and 3) full chain of custody. This presentation discusses how this program was built.

2:35 재고 관리:Biorepository의 재편, 정리통합, 품질 보증, 스페이스 비용

Sherilyn SawyerSherilyn J. Sawyer, Ph.D., Director, BWH/Harvard Cohorts Biorepository, Channing Division of Network Medicine, Brigham and Women's Hospital

Space and organization within the available space are two high-level concerns of the biorepository. We have recently undertaken a multiyear project to reorganize inventory in order to recover lost space and utilize space more efficiently. A cost/benefit analysis of this project contributes to understanding the true costs of space for biorepositories.

3:05 스폰서 제공 프레젠테이션

Speaker to be Announced

3:20 스폰서 제공 프레젠테이션

3:35 전시회장 휴식시간, 포스터 발표 관람

4:00 인폼드 콘센트(Informed Consent) 및 오래된 바이오뱅크 시료에 관한 재동의(Re-Consent) 획득에 이 용 가능한 웹기반 솔루션

Daniel ThielDaniel B. Thiel, Public Health Researcher, Health Services Organization and Policy, University of Michigan School of Public Health

Highlighting the results of a pilot web-based informed consent portal for legacy donors to the Michigan BioTrust for Health, this presentation explores practical and ethical challenges raised by informed consent for legacy donors to biobanks. In the case of Michigan's BioTrust, the legacy samples are residual dried bloodspots derived from state-mandated newborn screening. I also consider this experiment in light of broader implications for biobanks comprising legacy samples.

4:30 조직 은행, 바이오인포매틱스, 전자의무기록(EMR):맞춤형 의료의 전제조건

K. Stephen SuhK. Stephen Suh, Ph.D., Director, Genomics and Biomarkers Program, John Theurer Cancer Center, Hackensack University Medical Center

Personalized medicine promises patient-tailored treatments that enhance patient care and decrease overall treatment costs by focusing on genetics and "-omics" data obtained from patient biospecimens and records to guide therapy choices that generate good clinical outcomes. The approach relies on diagnostic and prognostic use of novel biomarkers discovered through combinations of tissue banking, bioinformatics and electronic medical records (EMRs).

5:00 패널 디스커션:효과적인 이용에 의한 바이오뱅크의 가치 확보

Biobanks are necessary and expensive research infrastructures. The ability to demonstrate effective utilization of biobanks is a quality measure that is essential for both financial and social sustainability. This panel discusses approaches for effective utilization of specimens from biobanks, both in the establishment of new biobanks and in the use of legacy collections.

Moderators:

Marianne-HendersonMarianne K. Henderson, MS, CPC, Chief, Division of Cancer Epidemiology & Genetics, Office of Division Operations and Analysis and the Center for Global Health, National Cancer Institute; Chair, Organizing Advisory Committee, ISBER



Marianna BledsoeMarianna J. Bledsoe, MA, Adjunct Assistant Professor, Department of Clinical Research and Leadership, George Washington University School of Medicine and Health Sciences; Co-Chair, Science Policy Committee, ISBER

Panelists:

Jeffrey OttoJeffrey Otto, MBA, Ph.D., National Director, Center for Translational Research, Institute for Research and Innovation, Catholic Health Initiatives

Sherilyn SawyerSherilyn J. Sawyer, Ph.D., Director, BWH/Harvard Cohorts Biorepository, Channing Division of Network Medicine, Brigham and Women's Hospital

K. Stephen SuhK. Stephen Suh, Ph.D., Director, Genomics and Biomarkers Program, John Theurer Cancer Center, Hackensack University Medical Center

Daniel ThielDaniel B. Thiel, Public Health Researcher, Health Services Organization and Policy, University of Michigan School of Public Health

Additional Panelists to be Announced

6:00 전시회장 환영 리셉션, 포스터 발표 관람

7:00 첫째날 종료


프리컨퍼런스 | 첫째날 | 둘째날 | 셋째날 | 포스트컨퍼런스 | 연사


7월 15일(수)

7:30 am 조찬 프레젠테이션(스폰서 모집중) 또는 커피

8:00 바이오뱅크 브레인스토밍:조찬 그룹 토론

커피와 함께하는 그룹 토론. 이 세션은 다양한 배경의 참가자가 각자의 생각과 경험을 공유하고, 초점토픽을 둘러싼 미래 협력 관계를 발전시키기 위해 참가자간 의견을 공유하고 문제의 해결책을 모색하는 형태로 진행

품질 시스템 - 바이오뱅크의 모든 요소가 의거하는 골격

Michael BreardMichael Breard, MS, MT(ASCP)SBB, CQA(ASQ), PMP(PMI), Vice President, Consulting Services and Sale, AABB

  • What is a quality system?
  • Why is quality important?
  • How do you achieve quality?
  • Is quality expensive?
  • What does it take to reach your quality goal?

Inventory Management and Data Annotation

Rajiv Dhir, M.D., MBA, Chief, Pathology, Shadyside Hospital, University of Pittsburgh Health Systems

  • What is inventory management and how do you currently address your needs?
  • What are the most common problems you have with inventory management?
  • What are the most common data annotation needs seen by you and how do you address them?
  • How do you provide data to your clients/investigators? Do you utilize honest brokers?

생체 시료, 바이오마커, 임상시험

9:00 의장 발언

Jeffrey OttoJeffrey Otto, MBA, Ph.D., National Director, Center for Translational Research, Institute for Research and Innovation, Catholic Health Initiatives

9:05 특별 강연:임상시험을 통한 정밀의학 전략의 전귀로의 중개

Lillian SiuLillian L. Siu, M.D., FRCPC, Professor, University of Toronto; Medical Oncologist, Princess Margaret Cancer Centre

Clinical trial frameworks focusing on interpatient heterogeneity include histology-based trials to evaluate therapeutic targeting of different molecular aberrations harbored by patients with a single tumor type ("umbrella trials"); as well as those that are histology-agnostic, aberrationspecific to encompass the assessment of similar molecular changes across different tumor types ("basket trials"). In this presentation, the benefits and challenges of genomics-based clinical trials are discussed, including a forecast into the next-generation precision medicine-based clinical research.


9:35 다중심형 림프종 치료제 임상시험의 상관 연구를 위한 생체 시료 조달

Koren MannKoren Mann, Ph.D., Assistant Professor, Oncology, Lady Davis Institute for Medical Research, McGill University

To develop novel agents in lymphoma, we must understand the molecular changes induced by these drugs, particularly in the context of clinical trials. We have developed a series of standard operating procedures (SOPs) to collect quality biospecimens for multiple downstream applications, including immunohistochemistry, exome sequencing, gene expression profiling, metabolomics and circulating tumor DNA. These SOPs were then validated in the context of the Q-CROC2 trial testing the efficacy of the histone deacetylase inhibitor, panobinostat, +/- rituximab in diffuse large B-cell lymphoma.

10:05 스폰서 제공 프레젠테이션

10:35 전시회장 휴식시간, 포스터 발표 관람

11:15 사례 연구 #1:생체 시료 과학, 임상시험, 정밀의학:실사례

Michael RoehrlMichael H. A. Roehrl, M.D., Ph.D., Director, UHN Program in BioSpecimen Sciences, University Health Network and University of Toronto

Anthony JoshuaAnthony M. Joshua, MBBS, Ph.D., Staff Oncologist/Affiliate Scientist, Princess Margaret Cancer Centre

We discuss the use of human biospecimens for translational research, in particular molecularly driven clinical trials and our Rapid Autopsy Program. We discuss optimal collection, use and quality of samples, patient enrollment and consent, and integrated clinical and research data collection and annotation.

12:00 pm 세션 종료

12:15 오찬 프레젠테이션(스폰서 모집중) 또는 개별 점심식사


생체 시료의 품질을 평가하기 위한 수단

2:00 의장 발언

Galen-HostetterGalen Hostetter, M.D., FCAP, Associate Director, Pathology Core, Van Andel Research Institute





2:05 연구 단계에서 임상 단계로의 이동:(사전)분석 변수와 어세이 개발

Veronique NeumeisterVeronique Neumeister, M.D., Laboratory Director, Specialized Translational Services Lab, Department of Pathology, Yale University School of Medicine

Companion diagnostic tests are critically dependent on tissue quality. However, tissue handling and processing are not always tightly controlled and pre-analytical variables can significantly alter tissue quality. This presentation focuses on the effects of (pre-)analytical variables in the diagnostic and research setting. Methodology and importance of quality control, optimization and standardization of tissue processing, biomarker validation and development of useful laboratory tests for the clinical setting will be discussed.

2:30 인간 바이오뱅크 업무의 참고가 되는 실험동물 모델

Galen-HostetterGalen Hostetter, M.D., FCAP, Associate Director, Pathology Core, Van Andel Research Institute

Experimental animal models have been widely used to inform veterinary and human pathophysiology with associated improved control of pre-analytic variables to include single marker QC probes or next-generation genomic sequencing of disaggregated tissue samples. We demonstrate animal experiments to combine tissue morphology and expressed protein by IHC, qualitative/quantitative measures of nucleic acids by RIN and Q-ratios, respectively, to assess effect of pre-analytic variables and provide the basis for standardized methods in tissue sample collection and processing.

2:55 가압 동결:동결 보존을 위한 새로운 방법

Nickolas GreerNickolas Greer, CSO, Rissali LLC

Chemical cryoprotectants are toxic to live cells, tissues and organs. Cryoprotectant toxicity increases with concentration. Both hydraulic pressure and cryoprotectants increase viscosity of aqueous solutions at the freezing point, inhibit ice crystal growth and induce vitrification of water. By applying pressure during freezing it may be possible to reduce concentration or eliminate cryoprotectants for preservation of viable biological materials, thereby solving the cryoprotectant toxicity problem.

3:20 혈액 은행에서 사용되는 변성 가공 솔루션으로 수집, 보존된 적색 세포의 마이크로플루이딕 디바이 스에 의한 평가

Dana SpenceDana Spence, Ph.D., Associate Professor, Department of Chemistry, Michigan State University

The collection and storage solutions used to process erythrocytes for storage in transfusion medicine contain levels of glucose that are nearly 10-15x higher than that found in the circulation of a healthy human. Here, data is presented demonstrating that maintenance of normoglycemic levels during the blood storage process helps to maintain certain properties of the stored cells, even beyond five weeks in storage.

3:45 스폰서 제공 프레젠테이션

4:15 전시회장 휴식시간, 포스터 발표 관람


4:50 특별 강연:다시설 공동 연구에서 면역 모니터링용 말초혈 표본에 영향을 미치는 해석전 변수

Amit Bar-OrAmit Bar-Or, M.D., FRCPC, Professor, Neurology & Neurosurgery; Director, Experimental Therapeutics Program and Scientific Director, Clinical Research Unit, Montreal Neurological Institute, McGill University

While there has been rapid growth in multicenter biomarker-development and immune-monitoring initiatives, including a major investment in procuring biological samples for cell-based assays, relatively little has been done to formally assess the impact of pre-analytical variables on functional immune responses within such samples. This presentation considers the impact of shipping approach and ambient temperature on such readouts.



사례 연구 :바이오뱅크와 이용자의 협력

Biomedical researchers and drug developers require accessible, highquality biospecimens that allow them to extract reliable and useful data. Oncology experts, for instance, use patient-derived tumor collections to connect datasets, pinpoint and assess variants within cancer patients post-diagnosis and zero in on the data that matter when tailoring therapies. Early, strategic collaborations with the biobanks that house specimens can be mutually beneficial, maximizing the financial and technological investments of the operation managers who collect, store, annotate and distribute the biological samples ("biobankers") and supporting the research goals of the scientists who need those samples ("biousers") - all to fulfill the promise of personalized medicine.


5:15 사례 연구 #2

6:00 세션 종료

6:00 쇼트코스 등록


6:15-9:30 디너 쇼트코스*

* 별도 참가 등록 필요


프리컨퍼런스 | 첫째날 | 둘째날 | 셋째날 | 포스트컨퍼런스 | 연사


7월 16일(목)

7:30 am 조찬 프레젠테이션(스폰서 모집중) 또는 커피


전문 분야의 바이오뱅크

8:00 의장 발언

Marianna BledsoeMarianna J. Bledsoe, MA, Adjunct Assistant Professor, Department of Clinical Research and Leadership, George Washington University School of Medicine and Health Sciences; Co-Chair, Science Policy Committee, ISBER

8:05 iPS 세포 바이오뱅크의 미래

Jonathan Y.H. LohJonathan Y.H. Loh, Ph.D., Assistant Professor, Department of Biological Sciences, National University of Singapore, A*STAR Institute of Molecular and Cell Biology

We have developed the technology for efficient derivation of transgene-free hiPSCs from human finger-prick blood. Finger-prick sample collection can be performed on a "do-it-yourself" basis by donors and sent to the hiPSC facility for reprogramming. We show that single-drop volumes of finger-prick samples are sufficient for performing cellular reprogramming, DNA sequencing, and blood serotyping in parallel. Our novel strategy has the potential to facilitate the development of large-scale hiPSC banking worldwide.

8:35 심장이식의 전귀 개선을 목적으로 한 바이오뱅크

Dawn BowlesDawn E. Bowles, Ph.D., Assistant Professor, Department of Surgery, Division of Surgical Sciences and Co-Director, Duke Human Heart Repository

A human cardiac transplant biorepository for research on improving cardiac transplantation outcomes has been established. Evidence indicates an association between the levels of cardiac injury biomarkers in the preservation/transportation fluid from the donor heart of transplant cases and the development of inadequate cardiac function post-implant in the recipient. Continued evaluation of the preservation fluid will lead to better understanding of preservation injury and optimization of preservation/transport solutions for cardiac transplant.

9:05 어린이와 여성을 위한 제도화된 병원 계획 입안과 시행:윤리면과 운영면의 문제

Suzanne VercauterenSuzanne Vercauteren, M.D., Ph.D., FRCPC, Head, Division of Hematopathology, BC Children's Hospital and Clinical Assistant Professor, Pathology and Laboratory Medicine, University of British Columbia

The BCCH BioBank's goal is to ethically collect biospecimens and clinical data from pediatric and adult patients with a range of conditions and store them systematically for future research. Its founding principles include public engagement, long-term sustainability and high-quality specimens. Its planning and implementation was a complex process that involved detailed consideration of the ethical issues concerning the different types of potential participants and careful consideration of the operational structure of the biobank.

9:35 스폰서 제공 프레젠테이션

10:05 전시회장 휴식시간, 포스터 발표 관람

10:45 University Health Network(UHN)의 비뇨생식기 바이오뱅크

Neil FleshnerNeil Fleshner, M.D., MPH, FRCSC, Chair, Urology, Department of Surgery, University of Toronto; Head, Urology, University Health Network; Director, GU BioBank, Princess Margaret Cancer Centre

The GU (genitourinary) BioBank is a predominantly bio-fluid-based program that follows consenting GU oncology participants over time, obtaining additional specimens and data at predefined intervals and upon any change in clinical state. This capacity for frequent and long-term follow-up has been made possible by integrating the BioBanking process with clinical care at UHN. The GU BioBank has garnered an incredible amount of interest in recent years. We share our experience in setting up and maintaining this patient-centered research program.

11:15 사례 연구 #3 (스폰서 모집중)

12:00 pm 세션 종료

12:15 오찬 프레젠테이션(스폰서 모집중) 또는 개별 점심식사


전문 분야의 바이오뱅크(계속)

2:00 의장 발언

Marianne-HendersonMarianne K. Henderson, MS, CPC, Chief, Division of Cancer Epidemiology & Genetics, Office of Division Operations and Analysis and the Center for Global Health, National Cancer Institute; Chair, Organizing Advisory Committee, ISBER



2:05 캐나다의 국립 제대혈 은행 개요

Heidi ElmoazzenHeidi Elmoazzen, Ph.D., Director, National Public Cord Blood Bank

Canadian Blood Services is building a National Public Cord Blood Bank which consists of five collection sites in four cities: Ottawa, Brampton, Edmonton and Vancouver, as well as two manufacturing facilities in Ottawa and Edmonton. An overview of the sources and use of hematopoietic stem cells as well as an overview of cord blood processing, cryopreservation and storage will be provided.

2:35 토론토 폐이식 바이오뱅크 프로젝트에서 수집되고 있는 시료

Sassan AzadSassan M. Azad, Project Manager, Clinical, Translational & Biobanking Research Office, Toronto Lung Transplant Program, Toronto General Hospital, University Health Network

The Toronto Lung Transplant Program, one of the world's largest, is supporting clinical research in end-stage lung disease and advancing lung transplantation. Two major areas that limit successful application of lung transplantation are ischemia reperfusion injury (IRI) and bronchiolitis obliterans (BO). Our work explores underlying mechanisms of both these injuries and the development of therapeutic strategies to prevent or reverse them. Our current research focus is on biomarker discovery and gene therapy in lung transplantation.

3:05 휴식시간, 전시회와 포스터 발표를 관람할 수 있는 마지막 기회


IT를 이용한 양질의 바이오뱅크 유지

4:15 확장 가능한 연구 데이터 리포지터리에서 임상 데이터 및 Biorepository 데이터 수집의 진전

Maureen E. Lane, Ph.D., Assistant Professor, Medicine; Director, Hem/Onc Translational Core Laboratory, The Leukemia Biorepository and Personalized Medicine Center, Weill Cornell Medical College

The Leukemia group at Weill Cornell Medical Center has been working with our information technology services (ITS) group to develop a Research Data Repository (RDR) that marries relevant clinical data with samples from our AML biorepository. This project is one of three pilot projects with a focus on supporting Precision Medicine and translational research at Weill Cornell.

4:40 중개연구와 기초 연구를 위한 데이터 뱅크와 Biorepository

Annmarie NowakAnnmarie Nowak, Coordinator & Director, Data Bank and Biorepository, Biobanking Systems Integration Cancer Prevention and Population Science, Roswell Park Cancer Institute

The Data Bank and BioRepository (DBBR) at Roswell Park Cancer Institute is a comprehensive data and sample bank, with biospecimens, epidemiologic and clinical information for investigators conducting translational research related to cancer prevention, etiology, detection and treatment. We discuss our recruitment, procurement and processing procedures, the structure and function of LIMS and the integration of clinical, research and biospecimen data.

5:05 양질의 바이오뱅크 실현과 바이오뱅크의 질 향상:CRIP ToolBox와 메타바이오뱅크 p-BioSPRE

Christina SchröderChristina Schröder, Ph.D., Head, Metabiobanks CRIP, Fraunhofer Institute for Cell Therapy and Immunology

While biobank registries and catalogs will at best allow queries for specific biobank collections or cohorts, trans-institutional metabiobanks enable parameterized, stratified, though privacy-preserving queries in connected biobanks on a case-by-case and sample-by-sample basis. Building such metabiobanks for a decade, and drawing upon broad expertise in semantic data integration across sectors relevant for translational biomedical research, we have developed the metabiobank software suite "CRIP Toolbox". We showcase p-BioSPRE, the metabiobank setup for the EU FP 7-funded project p-medicine, as a multipurpose tool to internationally access and promote quality biobanks online.

5:30 컨퍼런스 폐막


프리컨퍼런스 | 첫째날 | 둘째날 | 셋째날 | 포스트컨퍼런스 | 연사


포스트컨퍼런스 이벤트

7월 17일(금)


바이오뱅크를 이용한 연구을 위한 인폼드 콘센트의 내용과
절차 요건**

8:30 am-5:00 pm



This course presents the elements of the informed consent document and the components of the process, specifically as they relate to biobanking studies.

Instructor: Elizabeth Ronk Nelson, MPH, Barnett International


Participants will receive 7 hours (0.7 CEUs) from Accreditation Council for Pharmacy Education for full participation. For further information please visit barnettinternational.com

* 별도 참가 등록 필요



프리컨퍼런스 | 첫째날 | 둘째날 | 셋째날 | 포스트컨퍼런스 | 연사

* 주최측 사정에 따라 사전 예고없이 프로그램이 변경될 수 있습니다.

Choose your language
Traditional Chinese
Simplified Chinese
Japanese
English

Co-Hosted by
University Health Network logo

» 미디어 파트너

Catalog


국제컨퍼런스
Gii Event
이벤트 캘린더
메일링 서비스
메일링 서비스